WuXi Biologics (Cayman) Inc.

WXXWY

$13.33

Updated: 24/09/2026, 03:40:02

Market Cap

$27.37B

Sector

Healthcare

Industry

Biotechnology

Country

Stock valuation chart

One-year closing share-price history for WXXWY

Company Profile

WuXi Biologics (Cayman) Inc. delivers integrated solutions covering the entire lifecycle of biological drug development, from initial discovery to full-scale manufacturing. These services are provided to clients worldwide, with a significant presence in China, North America, and Europe. Beyond its core offerings, the company engages in various specialized activities, including offering expert advice on biopharmaceutical technology, managing international sales agreements, and developing and providing advanced testing solutions. It also handles sales and marketing efforts, supports clinical trials and production of biologics, produces and distributes medical goods, operates a contract development and manufacturing organization (CDMO) for vaccines, and supplies essential materials to the industry. Founded in 2014, WuXi Biologics is based in Wuxi, China, and maintains strategic alliances with partners such as ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc.

USD

OTC

CEO: Zhisheng Chen

Employees: 13,252

https://www.wuxibiologics.com

Asset Summaries

Latest generated summaries for WXXWY

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for WXXWY.

Share price: $13.33
Market cap: $27.37B
Exchange: OTC
Currency: USD
CEO: Zhisheng Chen
Employees: 13,252
IPO date: 18/12/2017
Beta: 0.598
Last dividend: $0.00
Day range: $13.29 – $13.74
52-week range: $7.30 – $13.78
1-day performance: -1.48%
1-year performance: 82.60%
Current drawdown (1Y): -3.27%
CIK: N/A
CUSIP: 98260N108
ISIN: US98260N1081
Created: 07/12/2025, 15:08:48
Last update: 24/09/2026, 03:40:02

Track WuXi Biologics (Cayman) Inc. with an AI analyst

See which prediction-market events move WXXWY, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to WXXWY from your Railway `news_articles` table.

WuXi Biologics Ireland Wins Top Honors at the 2026 Life Sciences Industry Awards

PRNewsWire • STOCK • 08/06/2026, 06:09:00

WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities

PRNewsWire • STOCK • 27/05/2026, 07:14:00

WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics

PRNewsWire • STOCK • 23/04/2026, 04:14:00

WuXi Biologics (Cayman) Inc. (WXXWY) Q4 2025 Earnings Call Transcript

Seeking Alpha • STOCK • 25/03/2026, 21:55:57

WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture

PRNewsWire • STOCK • 25/03/2026, 07:22:00

WuXi Biologics Reports Record 2025 Annual Results

PRNewsWire • STOCK • 24/03/2026, 08:44:00

WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation

PRNewsWire • STOCK • 13/03/2026, 00:09:00

WuXi Biologics Awarded EcoVadis Platinum Medal for Third Consecutive Year, Ranking Among Top 1% Globally

PRNewsWire • STOCK • 08/02/2026, 22:30:00